First-line HER2-directed triplet moves into advanced gastric and GEJ adenocarcinoma
A phase II study in HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma tested a first-line regimen built around a HER2-directed antibody-drug conjugate, a PD-1 inhibitor, and an oral fluoropyrimidine. The combination paired disitamab vedotin with tislelizumab and S-1, aiming to deepen tumor control in a disease where HER2 biology can be leveraged at the same time as immune evasion pathways are blocked.
The strategy is biologically coherent. HER2 amplification and overexpression identify a tumor surface target that can be attacked with payload delivery, while PD-1 blockade can reinvigorate antitumor T-cell activity inside an immunologically hostile gastric cancer microenvironment. S-1 adds a cytotoxic backbone commonly used in gastrointestinal oncology, creating a triplet that is intended to work through complementary mechanisms rather than a single pathway.
The regimen was studied as a single-arm, multicenter, phase II trial. Patients received disitamab vedotin 2.5 mg/kg on day 1, tislelizumab 200 mg on day 1, and S-1 40–60 mg twice daily on days 1 through 14 of each 21-day cycle. The primary endpoint was confirmed objective response rate by independent central review using RECIST v1.1. Secondary endpoints included progression-free survival, overall survival, duration of response, and safety.
Enrollment profile and HER2 selection criteria
Fifty-seven patients entered the study. The median age was 65 years, placing the cohort squarely in the older adult population routinely seen in real-world upper gastrointestinal oncology practice. HER2 expression was enriched at the high end of the spectrum: 71.9% had IHC 3+ disease, 17.5% had IHC 2+/ISH-positive tumors, and 10.5% had IHC 2+/ISH-negative tumors. The inclusion of IHC 2+ disease regardless of ISH status broadens clinical relevance, because it reflects a population in which HER2 biology is present but not always cleanly binary.
Baseline PD-L1 combined positive score data were also collected, though the excerpt available here stops before the full biomarker distribution is shown. Even without the complete biomarker table, the design makes clear that the investigators were attempting to position immune checkpoint inhibition in a HER2-selected setting where antigen release from ADC-induced tumor kill could plausibly augment immune priming.
One sentence captures the clinical tension in the study design: this is not a simple chemotherapy substitution.
Why an ADC plus checkpoint blockade is attractive in gastric cancer
The appeal of the combination rests on several biologic layers. Disitamab vedotin delivers cytotoxic drug directly to HER2-expressing cells, potentially increasing intratumoral antigen release and inflammatory signaling. Tislelizumab then inhibits PD-1-mediated suppression of T-cell activity, which may matter in a disease that often remains immunologically resistant despite standard chemotherapy. S-1 contributes systemic cytotoxic pressure and can help control microscopic and measurable disease across metastatic sites.
In practical terms, the regimen tries to convert HER2 into both a target and a vulnerability. The ADC component can produce direct tumor cell death, while checkpoint inhibition may extend that effect beyond the cells immediately exposed to the antibody-drug conjugate. In gastric and GEJ adenocarcinoma, where first-line treatment has long depended on fluoropyrimidine- and platinum-based chemotherapy with or without HER2-directed biologics, this trial reflects a newer therapeutic logic: intensify local tumor targeting while engaging the immune system earlier in the disease course.
What the available excerpt does and does not show
The provided abstract text stops after the baseline biomarker description and does not include the efficacy or safety outcomes. Because of that truncation, no response rate, survival estimate, adverse event rate, or discontinuation figure can be stated here without risking fabrication. The study was explicitly powered around confirmed response and included PFS, OS, duration of response, and safety as secondary endpoints, but the numeric results are not visible in the excerpt supplied for rewriting.
The missing outcome section matters because a triplet like this can only be judged by the balance it strikes between depth of response and tolerability. In advanced gastric cancer, higher activity is clinically meaningful only if the regimen can be delivered without unacceptable hematologic toxicity, neuropathy, immune-related adverse effects, or treatment-limiting fatigue and gastrointestinal adverse events. Those are the exact domains this class of regimen must navigate, especially when an ADC and an immune checkpoint inhibitor are combined with oral fluoropyrimidine therapy.
How the trial fits the current treatment problem
Advanced HER2-overexpressing gastric and GEJ adenocarcinoma remains a difficult disease to control for long periods. HER2 targeting alone has not fully solved the problem of early progression, heterogeneous resistance, and metastatic escape. A regimen that combines targeted delivery, immune modulation, and chemotherapy is an attempt to broaden pressure on the tumor from several angles at once.
The phase II format is appropriate for that question. It is large enough to detect a signal of antitumor activity and to characterize early safety, but it still leaves open the issue of whether the benefit can be reproduced in a randomized comparison against established first-line therapy. Single-arm data can support hypothesis generation and later phase development, yet they cannot establish superiority over standard treatment on their own.
Even so, the patient population selected here is clinically recognizable: older adults with advanced HER2-overexpressing disease, the majority with IHC 3+ tumors, treated in a multicenter setting using a regimen that was designed to test whether HER2-directed payload delivery can be paired with immune checkpoint inhibition at the start of therapy. The result is a clear signal of where the field is moving, even though the quantitative outcome section is absent from the excerpt at hand.
The unresolved issue is the size of the efficacy signal and whether toxicity stayed compatible with routine first-line delivery.